MedPath

A Study of HIV and Cytomegalovirus (CMV) in HIV-Infected Patients

Completed
Conditions
Cytomegalovirus Infections
HIV Infections
Registration Number
NCT00001089
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Brief Summary

To define relationships between 1) HIV load and risk of CMV disease, 2) CMV load and the risk of developing CMV disease, and 3) CMV load and HIV load. To establish threshold CMV and HIV load values in peripheral blood fractions that are associated with development of CMV end-organ disease. To define the natural history of CMV diseases in the context of highly active antiretroviral therapy (HAART).

Establishment of threshold CMV and HIV load values associated with CMV disease would facilitate identification of HIV-infected individuals truly at risk for CMV disease in whom targeted prophylactic interventions to prevent CMV disease would be indicated. These studies would also further the understanding of the natural history of CMV disease within the context of AIDS. Natural history studies conducted prior to the advent of highly active antiretroviral therapy (HAART; i.e., 3-drug regimens that include HIV reverse transcriptase and protease inhibitors) have demonstrated that the risk for developing CMV disease increases with progression of HIV disease and with declining CD4 counts. Presently the need exists to define the natural history of CMV disease in patients with AIDS within the context of HAART.

Detailed Description

Establishment of threshold CMV and HIV load values associated with CMV disease would facilitate identification of HIV-infected individuals truly at risk for CMV disease in whom targeted prophylactic interventions to prevent CMV disease would be indicated. These studies would also further the understanding of the natural history of CMV disease within the context of AIDS. Natural history studies conducted prior to the advent of highly active antiretroviral therapy (HAART; i.e., 3-drug regimens that include HIV reverse transcriptase and protease inhibitors) have demonstrated that the risk for developing CMV disease increases with progression of HIV disease and with declining CD4 counts. Presently the need exists to define the natural history of CMV disease in patients with AIDS within the context of HAART.

In this prospective observational study, HIV-infected patients who are CMV-seropositive with no clinical symptoms of CMV disease at entry are followed for three years or until the diagnosis of CMV end-organ disease or death, whichever comes first. Clinical evaluations are performed at baseline and every 8 weeks. Blood samples for virologic studies are taken every 16 weeks.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
400
Inclusion Criteria

Not provided

Read More
Exclusion Criteria

Not provided

Read More

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (36)

Louis A Weiss Memorial Hosp

🇺🇸

Chicago, Illinois, United States

Univ of Miami School of Medicine

🇺🇸

Miami, Florida, United States

Division of Inf Diseases/ Indiana Univ Hosp

🇺🇸

Indianapolis, Indiana, United States

Methodist Hosp of Indiana / Life Care Clinic

🇺🇸

Indianapolis, Indiana, United States

Beth Israel Deaconess - West Campus

🇺🇸

Boston, Massachusetts, United States

Univ of Cincinnati

🇺🇸

Cincinnati, Ohio, United States

Mem Sloan - Kettering Cancer Ctr

🇺🇸

New York, New York, United States

Los Angeles County - USC Med Ctr

🇺🇸

Los Angeles, California, United States

San Mateo AIDS Program / Stanford Univ

🇺🇸

Stanford, California, United States

UCLA CARE Ctr

🇺🇸

Los Angeles, California, United States

Harbor UCLA Med Ctr

🇺🇸

Torrance, California, United States

Children's Hosp of Washington DC

🇺🇸

Washington, District of Columbia, United States

Emory Univ Hosp / Pediatrics

🇺🇸

Atlanta, Georgia, United States

Indiana Univ Hosp

🇺🇸

Indianapolis, Indiana, United States

Univ of Southern California / LA County USC Med Ctr

🇺🇸

Los Angeles, California, United States

Bellevue Hosp / New York Univ Med Ctr

🇺🇸

New York, New York, United States

St Louis Regional Hosp / St Louis Regional Med Ctr

🇺🇸

St. Louis, Missouri, United States

St Paul Ramsey Med Ctr

🇺🇸

St. Paul, Minnesota, United States

Queens Med Ctr

🇺🇸

Honolulu, Hawaii, United States

Community Health Network Inc

🇺🇸

Rochester, New York, United States

Univ of Pennsylvania at Philadelphia

🇺🇸

Philadelphia, Pennsylvania, United States

Univ of Rochester Medical Center

🇺🇸

Rochester, New York, United States

Montefiore Med Ctr Adolescent AIDS Program

🇺🇸

Bronx, New York, United States

St Vincent's Hosp / Mem Sloan-Kettering Cancer Ctr

🇺🇸

New York, New York, United States

Johns Hopkins Hosp

🇺🇸

Baltimore, Maryland, United States

Univ of Tennessee / E Tennessee Comprehensive Hemophilia Ctr

🇺🇸

Knoxville, Tennessee, United States

Univ of Alabama at Birmingham

🇺🇸

Birmingham, Alabama, United States

Stanford at Kaiser / Kaiser Permanente Med Ctr

🇺🇸

San Francisco, California, United States

Charity Hosp / Tulane Univ Med School

🇺🇸

New Orleans, Louisiana, United States

Children's Hosp of Denver

🇺🇸

Denver, Colorado, United States

Hennepin County Med Clinic

🇺🇸

Minneapolis, Minnesota, United States

Univ of North Carolina

🇺🇸

Chapel Hill, North Carolina, United States

Harvard (Massachusetts Gen Hosp)

🇺🇸

Boston, Massachusetts, United States

Boston Med Ctr

🇺🇸

Boston, Massachusetts, United States

Beth Israel Deaconess Med Ctr

🇺🇸

Boston, Massachusetts, United States

Julio Arroyo

🇺🇸

West Columbia, South Carolina, United States

© Copyright 2025. All Rights Reserved by MedPath